Key result
SNTA1-deficient human cardiomyocytes exhibited a hypertrophic phenotype, lower cardiac contractility, and abnormal calcium handling, which were partially improved by early treatment with ranolazine.
Why the study?
Previous research on SNTA1 was based on non-human cardiomyocytes, leaving the phenotype of SNTA1 deficiency in human cardiomyocytes unknown.
Does SNTA1 knockout induce a hypertrophic phenotype and calcium handling disorder in human embryonic stem cell-derived cardiomyocytes?
Does SNTA1 knockout induce a hypertrophic phenotype and calcium handling disorder in human embryonic stem cell-derived cardiomyocytes?
SNTA1-deficient human cardiomyocytes exhibit a hypertrophic phenotype and impaired calcium handling that can be improved by ranolazine, providing a novel human cell model for studying myocardial diseases.
Answers are grounded in this paper and cite their sources.
Human SNTA1-KO cardiomyocyte model now available; leaves open validation in patients and therapeutic testing.
BACKGROUND: α-1-syntrophin (SNTA1), a protein encoded by SNTA1, is highly expressed in human cardiomyocytes. Mutations in SNTA1 are associated with arrhythmia and cardiomyopathy. Previous research on SNTA1 has been based on non-human cardiomyocytes. This study was designed to identify the phenotype of SNTA1-deficiency using human cardiomyocytes. METHODS: SNTA1 was knocked out in the H9 embryonic stem cell line using the CRISPR-Cas9 system. H9SNTA1KO cells were then induced to differentiate into cardiomyocytes using small molecule inhibitors. The phenotypic discrepancies associated with SNTA1-deficient cardiomyocytes were investigated. RESULTS: SNTA1 was truncated at the 149th amino acid position of PH1 domain by a stop codon (TGA) using the CRISPR-Cas9 system. SNTA1-deficiency did not affect the pluripotency of H9SNTA1KO, and they retain their in vitro ability to differentiate into cardiomyocytes. However, H9SNTA1KO derived cardiomyocytes exhibited hypertrophic phenotype, lower cardiac contractility, weak calcium transient intensity, and lower level of calcium in the sarcoplasmic reticulum. Early treatment of SNTA1-deficient cardiomyocytes with ranolazine improved the calcium transient intensity and cardiac contractility. CONCLUSION: SNTA1-deficient cardiomyocytes can be used to research the etiology, pathogenesis, and potential therapies for myocardial diseases. The SNTA1-deficient cardiomyocyte model suggests that the maintenance of cardiac calcium homeostasis is a key target in the treatment of myocardial-related diseases.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2022) studied SNTA1-deficiency / Hypertrophic phenotype. SNTA1 knockout vs. Wild-type cardiomyocytes was evaluated on Hypertrophic phenotype and calcium handling. SNTA1-deficient human cardiomyocytes exhibited a hypertrophic phenotype, lower cardiac contractility, and abnormal calcium handling, which were partially improved by early treatment with ranolazine.
Synapse has enriched 10 related papers. Consider them for comparative context: